Reviewing Regeneron Pharmaceuticals (NASDAQ:REGN) and Oragenics (NYSE:OGEN)

Regeneron Pharmaceuticals (NASDAQ:REGN) and Oragenics (NYSE:OGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Oragenics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$13.12 billion	7.54	$3.95 billion	$34.75	25.93
Oragenics	$40,000.00	120.96	-$20.66 million	($9.25)	-0.12

Regeneron Pharmaceuticals has higher revenue and earnings than Oragenics. Oragenics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Oragenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	30.14%	17.61%	13.76%
Oragenics	N/A	-397.35%	-246.95%

Institutional & Insider Ownership

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.7% of Oragenics shares are owned by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 24.6% of Oragenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Regeneron Pharmaceuticals and Oragenics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	1	4	14	0	2.68
Oragenics	0	0	0	0	N/A

Regeneron Pharmaceuticals presently has a consensus price target of $970.57, indicating a potential upside of 7.70%. Given Regeneron Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Oragenics.

Summary

Regeneron Pharmaceuticals beats Oragenics on 10 of the 13 factors compared between the two stocks.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

About Oragenics

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.